| Literature DB >> 33272216 |
Rakhshanda Erum1, Farkhunda Samad2, Adnan Khan2, Shahana Urooj Kazmi2.
Abstract
BACKGROUND: Surgical site infection (SSI) is a crucial dilemma of surgery. Patients with SSIs not only face difficulty in treatment but also bear extra cost with high mortality rate. Resistant strains of Candida have emerged as an important nosocomial pathogen. Proteinase and phospholipase are exo- enzymes of Candida species, have importance with respect to their contribution in diseases. This study focused on prevalence of Candida species in surgical wound, their resistance to antifungal drugs, co-relation of these resistance with virulence potential of Candida species and comparison of production level of exo-enzymes of Candida species isolated from patients with SSIs and healthy individuals to highlights their role in SSIs.Entities:
Keywords: Antifungal drug resistance; Candida species; Phospholipase; Proteinase; Surgical site infection
Mesh:
Substances:
Year: 2020 PMID: 33272216 PMCID: PMC7713141 DOI: 10.1186/s12866-020-02045-6
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Age and Sex Distribution of Patients with Surgical Site Infection
| Age in years | Male (%) | Female (%) | Patients |
|---|---|---|---|
| 0–19 | 58 (12.88%) | 30 (6.66%) | 88 (19.55%) |
| 20–39 | 149 (33.11%) | 90 (20%) | 239 (53.11%) |
| 40–59 | 45 (10%) | 48 (10.66%) | 93 (20.66%) |
| 60–79 | 17 (3.77%) | 13 (3%) | 30 (6.66%) |
Numbers in parentheses are percentages
Reason for Surgery
| Types of Surgery | Patients (n = 450) | Percentage |
|---|---|---|
| Disease | 368 | 81.78 |
| Gunshot | 58 | 12.88 |
| Accident | 24 | 5.34 |
Disease Distribution Associated with Surgical Site Infections
| Disease | Patients ( | Percentage (%) |
|---|---|---|
| Intestinal Perforation | 103 | 28 |
| Intestinal Obstruction | 70 | 19 |
| Appendicitis | 52 | 14 |
| Peritonitis | 41 | 11 |
| Intestinal Hernia | 29 | 8 |
| Cholecystitis | 29 | 8 |
| Ulcerative Colitis | 18 | 5 |
| Others | 26 | 7 |
Co-morbid Conditions of Patients with Surgical Site Infection
| Diseases | Patients (n = 450) | Percentage (%) |
|---|---|---|
| Diabetes | 54 | 12 |
| Mental disorder | 11 | 2.44 |
| Arthritis | 27 | 6 |
| Obesity | 18 | 4 |
| Cardiovascular diseases | 14 | 3.11 |
| Ulcer | 7 | 1.55 |
| No comorbidity | 319 | 70.88 |
Fig. 1Ratio of Growth of Pathogens Isolated from Patients with SSIs
Spectrum of Pathogens in Pus Samples of Surgical Wound Patients
| Isolates | Percentage | |
|---|---|---|
| 147 | 24 | |
| 128 | 20.94 | |
| 110 | 18 | |
| 98 | 16 | |
| 55 | 9 | |
| 37 | 6 | |
| Coagulase-negative | 21 | 3.43 |
| Other Pathogens | 15 | 2.45 |
Fig. 2Prevalence of C. albicans in Surgical Site Infection (SSIs) and in Healthy Individuals (HI)
Spectrum of Candida Species in Pus Samples of Surgical Wound Patients
| Isolates | Percentage (%) | |
|---|---|---|
| 54 | 42.18 | |
| 32 | 25 | |
| 17 | 13.28 | |
| 13 | 10.16 | |
| 12 | 9.38 |
Antifungal Susceptibility Profile of Candida spp. Isolated from Surgical Wound Patients
| Fluconazole | Voriconazole | Itraconazole | ||||
|---|---|---|---|---|---|---|
| S | R | S | R | S | R | |
| 48 (88.88%) | 6 (11.11%) | 54 (100%) | 0 (0%) | 53 (98.14) | 1 (1.85%) | |
| 26 (81.25%) | 6 (18.75%) | 29 (90.62%) | 3 (9.37%) | 28 (87.5) | 4 (12.5%) | |
| 11 (91.66%) | 1 (8.33%) | 11 (91.66%) | 1 (8.33%) | 10 (83.33%) | 2 (16.66%) | |
| 0 (0%) | 13 (100%) | 12 (92.30%) | 1 (7.69%) | 13 (100%) | 0 (0%) | |
| 17 (100%) | 0 (0%) | 17 (100%) | 0 (0%) | 17 (100) | 0 (0%) | |
S Sensitivity, R Resistance, numbers in parentheses are percentages
MICs of Antifungal Agents against C. albicans Isolated from Surgical Wound Patients
| Antifungal drugs | MIC Range (μg/ml) | MICs μg/ml | Resistant strains% | |
|---|---|---|---|---|
| MIC 50 MIC90 | ||||
| Fluconazole | 0.125–16 | 2 | 8 | 6 |
| Voriconazole | 0.03–0.5 | 0.06 | 0.5 | 0 |
| Itraconazole | 0.06–0.5 | 0.125 | 0.5 | 0 |
| Amphotericin B | 0.03–0.25 | 0.06 | 0.25 | 0 |
Prevalence of Phospholipase and Protienase Producing Candida species in Surgical Wound Patients
| Extracellular enzymes | Non-albicans | |
|---|---|---|
| Phospholipase | 46 (85.18%) | 20 (27.02%) |
| Proteinase | 49 (90.74%) | 52 (70.27%) |
Production of Phospholipase in non-albicans Candida species
| Non-albicans | Phospholipase producing strains ( |
|---|---|
Phospholipase and Proteinase Activity of C. albicans Isolates from Patients with Surgical Wound and Healthy Individuals
| Producers | Non producers | Pz Ranged | |
|---|---|---|---|
| Surgical wound (n = 54) | |||
| Proteinase | 49 (90.74%) | 5 (9.25%) | 0.17–0.81 |
| Phospholipase | 46 (85.18%) | 8 (14.81%) | 0.39–0.82 |
| Healthy subjects (n = 20) | |||
| Proteinase | 14 (70.0%) | 6 (30.0%) | 0.44–0.62 |
| Phospholipase | 12 (60.0%) | 8 (40.0%) | 0.57–0.93 |
Enzymatic Activity (mm) Exhibited by C. albicans Isolated from Patients with Surgical Wound and Healthy Individuals
| Pz Value | Phospholipase | Proteinase | |||
|---|---|---|---|---|---|
| Surgical wound | Healthy Individual | Surgical wound isolates (n = 54) | Healthy Individual | ||
| < 0.69 | ++++ | 25 (54.34) | 3 (25.0) | 34 (69.38) | 2 (14.28) |
| 0.70–0.79 | +++ | 11 (23.91) | 5 (41.66) | 8 (16.32) | 5 (37.71) |
| 0.80–0.89 | ++ | 6 (13.04) | 3 (25.0) | 5 (10.20) | 4 (28.57) |
| 0.90–0.99 | + | 4 (8.69) | 1 (8.33) | 2 (4.08) | 3 (21.42) |
| 1.00 | – | 8 (14.81) | 8 (40.0) | 5 (9.25) | 7 (30.0) |
Pz Value = Enzymatic activity zone, Numbers in parentheses are percentages
Fig. 3Phospholipase Production in Fluconazole Resistant and Fluconazole Sensitive Strains of C. albicans